βIII-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma

World Journal of Urology

Volumn 33, Issue 10, 2015, Pages 1561-1569

  Quaas, Alexander ^a   Rahvar, Amir Hossein ^a   Burdelski, Christoph ^a   Koop, Christina ^a   Eichelberg, Christian ^a   Rink, Michael ^a   Dahlem, Roland ^a   Schlomm, Thorsten ^a   Tsourlakis, Maria Christina ^a   Simon, Ronald ^a   Minner, Sarah ^a   Sauter, Guido ^a   Steurer, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Microtubules; Renal cell cancer; Survival; TMA; III tubulin

Indexed keywords

TUBB3 PROTEIN, HUMAN; TUBULIN; TUMOR MARKER;

AGED; BIOSYNTHESIS; CANCER STAGING; CARCINOMA, RENAL CELL; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; FOLLOW UP; GERMANY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SWITZERLAND; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWITZERLAND; TUBULIN;

EID: 84942509462     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1463-6     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300. doi:10.3322/caac.20073
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027
3. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of taxol resistance related to microtubules. Oncogene 22(47):7280–7295. doi:10.1038/sj.onc.1206934
4. Katsetos CD, Legido A, Perentes E, Mork SJ (2003) Class III beta-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor neuropathology. J Child Neurol 18(12):851–866 (discussion 867)
5. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, Cascon A, Robledo M, Rodriguez-Antona C (2010) Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton 67(4):214–223. doi:10.1002/cm.20436
6. Ferrandina G, Legge F, Salutari V, Paglia A, Testa A, Scambia G (2006) Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 42(14):2296–2302. doi:10.1016/j.ejca.2006.03.025
7. Hetland TE, Hellesylt E, Florenes VA, Trope C, Davidson B, Kaern J (2011) Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol 42(7):1019–1026. doi:10.1016/j.humpath.2010.10.025
8. Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ (2010) Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J thorac oncol 5(3):320–325. doi:10.1097/JTO.0b013e3181ce684f
9. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW (2012) Association between class III beta-tubulin expression and response to paclitaxel/vinorelbine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1):9–15. doi:10.1016/j.lungcan.2012.01.005
10. Zhou J, Li J, Wang Z, Yin C, Zhang W (2012) Metadherin is a novel prognostic marker for bladder cancer progression and overall patient survival. Asia Pac j clin oncol 8(3):e42–e48. doi:10.1111/j.1743-7563.2012.01541.x
11. Zheng WE, Chen H, Yuan SF, Wu LL, Zhang W, Sun HY, Chen WJ (2012) Overexpression of betaIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. J BUON 17(2):284–290
12. Zhang P, Ma X, Song E, Chen W, Pang H, Ni D, Gao Y, Fan Y, Ding Q, Zhang Y, Zhang X (2013) Tubulin cofactor a functions as a novel positive regulator of ccRCC progression, invasion and metastasis. Int j cancer. doi:10.1002/ijc.28306
13. Ferguson RE, Taylor C, Stanley A, Butler E, Joyce A, Harnden P, Patel PM, Selby PJ, Banks RE (2005) Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression. Clin cancer res 11(9):3439–3445. doi:10.1158/1078-0432.CCR-04-2049
14. Minner S, Rump D, Tennstedt P, Simon R, Burandt E, Terracciano L, Moch H, Wilczak W, Bokemeyer C, Fisch M, Sauter G, Eichelberg C (2012) Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer 118(5):1268–1275. doi:10.1002/cncr.26436
15. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655–663
16. Ploussard G, Terry S, Maille P, Allory Y, Sirab N, Kheuang L, Soyeux P, Nicolaiew N, Coppolani E, Paule B, Salomon L, Culine S, Buttyan R, Vacherot F, de la Taille A (2010) Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res 70(22):9253–9264. doi:10.1158/0008-5472.CAN-10-1447
17. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, Brase JC, Liu AY, Schluter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G, Schlomm T (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 17(18):5878–5888. doi:10.1158/1078-0432.CCR-11-1251
18. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159(6):2249–2256
19. Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int j cancer 118(9):2190–2194
20. Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194(3):349–357. doi:10.1002/1096-9896(200107)194:3<349:AID-PATH887>3.0.CO;2-D
21. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, Gasser T, Mihatsch MJ, Kallioniemi OP, Sauter G (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–986
22. Simon R, Mirlacher M, Sauter G (2005) Tissue microarrays. Methods Mol Med 114:257–268. doi:10.1385/1-59259-923-0:257
23. Steurer S, Seddiqi AS, Singer JM, Bahar AS, Eichelberg C, Rink M, Dahlem R, Huland H, Sauter G, Simon R, Minner S, Burandt E, Stahl PR, Schlomm T, Wurlitzer M, Schluter H (2014) MALDI imaging on tissue microarrays identifies molecular features associated with renal cell cancer phenotype. Anticancer Res 34(5):2255–2261
24. Tsourlakis MC, Weigand P, Grupp K, Kluth M, Steurer S, Schlomm T, Graefen M, Huland H, Salomon G, Steuber T, Wilczak W, Sirma H, Simon R, Sauter G, Minner S, Quaas A (2013) betaIII-Tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion. Am J Pathol. doi:10.1016/j.ajpath.2013.11.007
25. Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D (2013) Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin cancer res 19(6):1587–1595. doi:10.1158/1078-0432.CCR-12-1359
26. Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G (2012) High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway. Mol Cancer Ther 11(5):1203–1213. doi:10.1158/1535-7163.MCT-11-0899
27. Katsetos CD, Herman MM, Mork SJ (2003) Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 55(2):77–96. doi:10.1002/cm.10116
28. Gao S, Zhao X, Lin B, Hu Z, Yan L, Gao J (2012) Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance. Tumour biol 33(5):1759–1765. doi:10.1007/s13277-012-0435-y
29. Carrara L, Guzzo F, Roque DM, Bellone S, Emiliano C, Sartori E, Pecorelli S, Schwartz PE, Rutherford TJ, Santin AD (2012) Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. Gynecol Oncol 125(1):231–236. doi:10.1016/j.ygyno.2011.12.446
30. Panda D, Miller HP, Banerjee A, Luduena RF, Wilson L (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91(24):11358–11362
31. Falconer MM, Echeverri CJ, Brown DL (1992) Differential sorting of beta tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. Cell Motil Cytoskeleton 21(4):313–325. doi:10.1002/cm.970210407
32. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM (2010) Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J cell biol 189(3):541–556. doi:10.1083/jcb.200909113
33. Schnaeker EM, Ossig R, Ludwig T, Dreier R, Oberleithner H, Wilhelmi M, Schneider SW (2004) Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 64(24):8924–8931. doi:10.1158/0008-5472.CAN-04-0324
34. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O’Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA (2010) Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463(7279):360–363. doi:10.1038/nature08672
35. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, Babb JS, Grizzle WE, Cairns P (2004) Promoter hypermethylation profile of kidney cancer. Clin cancer res 10(12 Pt 1):3972–3979. doi:10.1158/1078-0432.CCR-04-0175
36. Thoma CR, Matov A, Gutbrodt KL, Hoerner CR, Smole Z, Krek W, Danuser G (2010) Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. J cell biol 190(6):991–1003. doi:10.1083/jcb.201006059
37. Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE (2004) The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. Exp Cell Res 301(2):139–146. doi:10.1016/j.yexcr.2004.07.016
38. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90(20):9552–9556
39. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17(3):1061–1070
40. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9(2):168–175. doi:10.1016/S1470-2045(08)70029-9
41. Narvi E, Jaakkola K, Winsel S, Oetken-Lindholm C, Halonen P, Kallio L, Kallio MJ (2013) Altered TUBB3 expression contributes to the epothilone response of mitotic cells. Br J Cancer 108(1):82–90. doi:10.1038/bjc.2012.553
42. Lu Q, Luduena RF (1993) Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 18(3):173–182
43. Banerjee A, Roach MC, Trcka P, Luduena RF (1990) Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 265(3):1794–1799
44. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272(27):17118–17125
45. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J cancer 120(10):2078–2085. doi:10.1002/ijc.22557
46. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C (2005) Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4(12):2001–2007. doi:10.1158/1535-7163.MCT-05-0244
47. Mertens WC, Eisenhauer EA, Jolivet J, Ernst S, Moore M, Muldal A (1994) Docetaxel in advanced renal carcinoma. A phase II trial of the National Cancer Institute of Canada Clinical Trials Group. Ann oncol 5(2):185–187
48. Bruntsch U, Heinrich B, Kaye SB, de Mulder PH, van Oosterom A, Paridaens R, Vermorken JB, Wanders J, Franklin H, Bayssas M et al (1994) Docetaxel (Taxotere) in advanced renal cell cancer. A phase II trial of the EORTC Early Clinical Trials Group. Eur J Cancer 30A(8):1064–1067
49. Bylow KA, Atkins MB, Posadas EM, Stadler WM, McDermott DF (2009) Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. Clin genitourin cancer 7(1):39–42. doi:10.3816/CGC.2009.n.007
50. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, Ciobanu N, Grima K, Caliendo G, Cavasotto G et al (1993) Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2. J immunotherapy emphasis tumor immunol 13(4):275–281